Jeff Yorio, MD, discusses treatment combinations in BRAF-mutated melanoma.
Jeff Yorio, MD, medical oncologist, Texas Oncology, Austin Central, discusses treatment combinations in BRAF-mutated melanoma.
The various combination therapies available for the patients with melanoma harboring BRAF mutations include vemurafenib (Zelboraf) plus cobimetinib (Cotellic), dabrafenib (Tafinlar) plus trametinib (Mekinist), and binimetinib (Mektovi) plus encorafenib (Braftovi), Yorio explains, adding that they have produced high initial response rates in this patient population.
The majority of patients with BRAF-mutated melanoma can experience tumor shrinkage when treated with these targeted therapy combinations, Yorio continues. The up-front use of these agents can produce a rapid response in patients with a high tumor burden who are symptomatic from metastatic disease, Yorio concludes.